Peritoneal Carcinomatosis for many years has been considered “the final stage of the disease” as it is not susceptible to surgical treatment even though the peritoneum, for many patients, is the only site of illness in the absence of remote diffusion.
In the last decade, Cytoreductive Surgery (CRS) in association with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has been used to apply “Locoregional Therapy” in the treatment of peritoneal disease.
Today, CRS and HIPEC represent the standard of care for some peritoneal diffused pathology.
The purpose of this congress is to:
In the last decade, Cytoreductive Surgery (CRS) in association with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has been used to apply “Locoregional Therapy” in the treatment of peritoneal disease.
Today, CRS and HIPEC represent the standard of care for some peritoneal diffused pathology.
The purpose of this congress is to:
- Discuss the state of CRS and HIPEC in the treatment of resectable peritoneal carcinosis of gastrointestinal and gynecological origin;
- Emphasize the role of HIPEC in carcinomatosis prevention;
- Explore the innovative methods of Pressurized Intraperitoneal Aerosol (PIPAC) in the treatment of non-resectable peritoneal disease.
Peritoneal Carcinomatosis: State of the art and future prospects
Rome, 26th January 2018
Presidenti: Prof. Fabio Pacelli, Prof. Giovanni Scambia
Direttore Scientifico: Dr. Andrea Di Giorgio
